Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY20 results · Jan–Mar 2020
Astec LifeSciences reported revenue from operations of ₹180.57 crore (up 35.0% from Q4 FY19) and net profit of ₹31.18 crore (up 145.0% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 180.57 | 133.76 | +35.0% | 124.83 | +44.6% |
| Other income | 5.24 | 5.76 | −9.0% | 3.93 | +33.3% |
| Total income | 185.81 | 139.52 | +33.2% | 128.76 | +44.3% |
| Profit before tax | 39.63 | 20.22 | +96.1% | 15.61 | +153.9% |
| Net profit for the period | 31.18 | 12.73 | +145.0% | 12.17 | +156.3% |
| Attributable to shareholders of the company | 31.18 | 12.72 | +145.1% | 12.16 | +156.3% |
| EPS, basic (₹) | 15.94 | 6.50 | +145.2% | 6.22 | +156.3% |
| Net margin (%) | 17.3 | 9.5 | 9.7 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 180.18 | 133.76 | +34.7% | 124.83 | +44.3% |
| Other income | 5.24 | 5.74 | −8.7% | 3.93 | +33.3% |
| Total income | 185.43 | 139.50 | +32.9% | 128.76 | +44.0% |
| Profit before tax | 39.61 | 20.18 | +96.3% | 15.59 | +154.1% |
| Net profit for the period | 31.17 | 12.70 | +145.4% | 12.15 | +156.4% |
| EPS, basic (₹) | 15.94 | 6.50 | +145.2% | 6.21 | +156.7% |
| Net margin (%) | 17.3 | 9.5 | 9.7 |
Consolidated
- Filed with BSE
- 06 May 2020, 09:43 IST
- Board meeting
- 05 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 May 2020, 09:43 IST
- Board meeting
- 05 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE